License Agreement (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|
May 31, 2021 |
May 31, 2020 |
Mar. 31, 2024 |
Dec. 31, 2023 |
Mar. 31, 2023 |
Sep. 30, 2022 |
Mar. 31, 2024 |
Mar. 31, 2023 |
|
| Research and development expense | $ 748,339 | $ 1,089,342 | $ 3,081,231 | $ 4,183,038 | ||||
| Future milestone payments | $ 654,000 | $ 6,397,821 | ||||||
| Vernalis Development Limited [Member] | ||||||||
| Research and development expense | $ 200,000 | |||||||
| Development milestone payment | 29,900,000 | |||||||
| Vernalis Development Limited [Member] | IPO [Member] | ||||||||
| Number of shares of common stock | 192,857 | |||||||
| Future milestone payments | $ 1,400,000 | |||||||
| Vernalis Development Limited [Member] | Minimum [Member] | ||||||||
| Marketing authorization amount | 400,000 | |||||||
| Sales milestone payments | 10,000,000.0 | |||||||
| Cumulative annual net sales amount | 500,000,000.0 | |||||||
| Vernalis Development Limited [Member] | Maximum [Member] | ||||||||
| Marketing authorization amount | 3,000,000.0 | |||||||
| Sales milestone payments | 25,000,000.0 | |||||||
| Cumulative annual net sales amount | $ 1,000,000,000 | |||||||
| X | ||||||||||
- Definition Amount of development cost incurred in oil- and gas-producing activities. Includes capitalized cost and cost charged to expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The total expense recognized in the period for promotion, public relations, and brand or product advertising. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Cash receipts from customers during the current period which are usually for sales of goods and services. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Expenses recognized in the period that are directly related to the selling and distribution of products or services. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|